Kamada Ltd.
$8.32
0%
2026-04-21 07:44:00
www.kamada.com
NMS: KMDA
Explore Kamada Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$479.95 M
Current Price
$8.32
52W High / Low
$9.35 / $6.35
Stock P/E
23.76
Book Value
$4.66
Dividend Yield
3%
ROCE
7.92%
ROE
7.64%
Face Value
—
EPS
$0.35
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
462
Beta
0.31
Debt / Equity
4.3
Current Ratio
4.07
Quick Ratio
2.28
Forward P/E
14.31
Price / Sales
2.72
Enterprise Value
$425.85 M
EV / EBITDA
10.78
EV / Revenue
2.36
Rating
None
Target Price
$13
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Meaningful dividend yield is available.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
| 2. | Biofrontera Inc. | $1.09 | — | $12.81 M | — | -68.08% | -1.41% | $1.19 / $0.54 | $0.9 |
| 3. | Evolus, Inc. | $5.08 | — | $330.5 M | — | -24.97% | 587.36% | $12.28 / $3.86 | $-0.35 |
| 4. | United Therapeutics Corporation | $578.37 | 20.76 | $25.34 B | — | 20.73% | 19.71% | $607.89 / $272.12 | $162.6 |
| 5. | BioXcel Therapeutics, Inc. | $1.2 | — | $32.49 M | — | 557.9% | 74.14% | $8.08 / $1.01 | $-4.28 |
| 6. | Phibro Animal Health Corporation | $56.51 | 24.91 | $2.29 B | 0.85% | 10.35% | 31.8% | $60.08 / $16.16 | $8.2 |
| 7. | Prestige Consumer Healthcare Inc. | $58.68 | 14.89 | $2.78 B | — | 10.6% | 10.31% | $89.37 / $51.24 | $38.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 44.68 M | 47.01 M | 44.75 M | 44.02 M | 39.01 M | — |
| Operating Profit | 3.55 M | 7.82 M | 7.07 M | 7.79 M | 5.08 M | — |
| Net Profit | 3.56 M | 5.3 M | 7.38 M | 3.96 M | 3.81 M | — |
| EPS in Rs | 0.06 | 0.09 | 0.13 | 0.07 | 0.07 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 180.46 M | 160.95 M | 142.52 M | 129.34 M |
| Operating Profit | 26.23 M | 20.05 M | 10.06 M | 4.53 M |
| Net Profit | 20.2 M | 14.46 M | 8.28 M | -2.32 M |
| EPS in Rs | 0.35 | 0.25 | 0.14 | -0.04 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 378.71 M | 372.25 M | 354.91 M | 322.38 M |
| Total Liabilities | 109.64 M | 112.79 M | 110.89 M | 146.36 M |
| Equity | 269.07 M | 259.46 M | 244.02 M | 176.02 M |
| Current Assets | 193.07 M | 184.35 M | 169.96 M | 139 M |
| Current Liabilities | 47.39 M | 49.39 M | 49.59 M | 75.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 25.49 M | 47.59 M | 4.32 M | 28.59 M |
| Investing CF | -9.84 M | -10.74 M | -5.84 M | -3.78 M |
| Financing CF | -18.34 M | -13.91 M | 22.68 M | -9.34 M |
| Free CF | 15.64 M | 36.85 M | -1.53 M | 24.8 M |
| Capex | -9.85 M | -10.74 M | -5.85 M | -3.78 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 12.93% | 10.19% | — | — |
| Earnings Growth % | 74.58% | 456.92% | — | — |
| Profit Margin % | 8.99% | 5.81% | -1.79% | — |
| Operating Margin % | 12.46% | 7.06% | 3.5% | — |
| Gross Margin % | 43.47% | 38.94% | 36.11% | — |
| EBITDA Margin % | 17.27% | 15.75% | 8.36% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-03-23 | $0.25 |
| 2025-03-17 | $0.2 |
Stock Splits
No stock split history available.